2006
DOI: 10.1056/nejmoa064320
|View full text |Cite|
|
Sign up to set email alerts
|

Abstract: Lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab. (ClinicalTrials.gov number, NCT00078572 [ClinicalTrials.gov].).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

42
1,882
4
65

Year Published

2007
2007
2019
2019

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 3,051 publications
(1,993 citation statements)
references
References 16 publications
42
1,882
4
65
Order By: Relevance
“…Although a definitive safety profile for lapatinib must await the completion of several randomized phase III trials in breast cancer, it seems likely that the frequency of cardiac dysfunction will be low. Indeed, in a recent randomized trial in metastatic breast cancer, lapatinib was associated with only a 2.5% incidence of asymptomatic decreased LVEF 33 . How can this be reconciled with the more prominent cardiotoxicity of trastuzumab?…”
Section: Box 1 | Haematological Cancers: Good Targets For Tyrosine Kimentioning
confidence: 99%
“…Although a definitive safety profile for lapatinib must await the completion of several randomized phase III trials in breast cancer, it seems likely that the frequency of cardiac dysfunction will be low. Indeed, in a recent randomized trial in metastatic breast cancer, lapatinib was associated with only a 2.5% incidence of asymptomatic decreased LVEF 33 . How can this be reconciled with the more prominent cardiotoxicity of trastuzumab?…”
Section: Box 1 | Haematological Cancers: Good Targets For Tyrosine Kimentioning
confidence: 99%
“…Similarly, data suggest that lapatinib has a more‐favorable cardiac risk profile than trastuzumab7, 47 and the combination of both does not appear to be more cardiotoxic than the use of trastuzumab alone 6. Trials of ado‐trastuzumab suggest low rates of cardiotoxicity during follow‐up to date 9…”
Section: The Cardiac Risks Of Her2 Targeted Therapiesmentioning
confidence: 99%
“…Lapatinib is an oral small molecule that inhibits the tyrosine kinases of HER2 and epidermal growth factor receptor type 1 (HER1). Clinical studies have not demonstrated significant cardiotoxicity associated with use of lapatinib 7, 47…”
Section: Pathophysiologymentioning
confidence: 99%
See 1 more Smart Citation
“…In the clinic, lapatinib is active and improves time to disease progression in patients with advanced disease who have progressed to trastuzumab (Geyer et al, 2006).…”
Section: Introductionmentioning
confidence: 99%